Iradimed CORP Form 4 insider transactions

Director Hilda Scharen-Guivel of Iradimed Corporation received 1,811 restricted stock units on December 11, 2024, under the company's 2023 Equity Incentive Plan.

Director Monty K. Allen of Iradimed Corporation was granted 1,811 restricted stock units under the company's 2023 Equity Incentive Plan.

Director James B. Hawkins of Iradimed Corporation received 1,811 restricted stock units under the company's 2023 Equity Incentive Plan.

Iradimed's Chief Financial Officer, John Glenn, was granted restricted stock units and performance-based restricted stock units on December 11, 2024.

Iradimed Corp's executive, James B. Hawkins, received restricted stock units under the company's 2014 and 2023 Equity Incentive Plans, which will vest into common stock over the next two years.

Hilda Frederique Scharen-Guivel, an executive at Iradimed Corp, received restricted stock units that will vest in two equal annual installments starting December 7, 2024.

Anthony Vuoto, an executive at Iradimed Corp, received restricted stock units under the company's 2014 and 2023 Equity Incentive Plans, which will vest in installments and convert to common stock.

Iradimed Corp's executive, Monty K. Allen, received grants of common stock and restricted stock units under the company's 2014 and 2023 Equity Incentive Plans.

Iradimed's Chief Financial Officer, John Glenn, sold 2,500 shares of common stock at a weighted average price of $54.1797 on December 2, 2024.

Director Anthony Vuoto sold 2,690 shares of Iradimed Corp (IRMD) at an average price of $55.9911 on November 6, 2024.

Director Hilda Scharen-Guivel reports the vesting and conversion of restricted stock units into common stock of Iradimed Corporation.

Director Monty K. Allen of IRADIMED CORP sold 1,947 shares of common stock at a weighted average price of $43.3654 on June 3, 2024.